Altered gentamicin serum concentrations in obese pediatric patients

Related Experiment Video

Updated: Jun 7, 2026

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

Jamie J Choi1, Brady S Moffett, Erin J McDade

  • 1Department of Pharmacy, Texas Children's Hospital, Houston, TX, USA. jachoi@texaschildrens.org.

The Pediatric Infectious Disease Journal
|October 29, 2010
PubMed

Insights

Obese children require lower gentamicin doses per kilogram of body weight to achieve safe and effective serum concentrations. This study highlights the need for weight-based dosing adjustments in pediatric obesity to prevent toxicity and ensure therapeutic efficacy.

Area of Science:

  • Pediatric pharmacology
  • Clinical pharmacokinetics
  • Obesity medicine

Background:

  • Gentamicin is an antibiotic commonly used in pediatric patients.
  • Accurate dosing is crucial for efficacy and minimizing toxicity.
  • Obesity can alter drug pharmacokinetics, potentially affecting gentamicin levels.

Purpose of the Study:

  • To investigate gentamicin dosing and serum concentrations in obese pediatric patients.
  • To compare dosing strategies based on actual body weight versus ideal body weight.
  • To identify potential adjustments needed for gentamicin therapy in pediatric obesity.

Main Methods:

  • Retrospective case-cohort study design.
  • Inclusion of 50 obese pediatric patients aged 2-18 years.
  • Measurement of serum gentamicin peak and trough concentrations.

Main Results:

  • Obese pediatric patients exhibited significantly higher gentamicin serum peak concentrations.
  • Obese pediatric patients showed significantly higher gentamicin serum trough concentrations.
  • These higher concentrations were observed despite lower mg/kg actual body weight doses administered.

Conclusions:

  • Standard gentamicin dosing based on actual body weight may lead to supratherapeutic levels in obese children.
  • Dosing adjustments are necessary for obese pediatric patients to optimize gentamicin therapy.
  • Further research into weight-based dosing strategies for gentamicin in pediatric obesity is warranted.

More Related Videos

Galleria mellonella as an Antimicrobial Screening Model06:19

Galleria mellonella as an Antimicrobial Screening Model

Published on: October 11, 2024

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...